LogicBio Therapeutics Inc

NASDAQ:LOGC   9:39:36 AM EDT
3.03
-0.02 (-0.66%)
Earnings Announcements

Logicbio Therapeutics Reports Third Quarter 2021 Financial Results And Highlights Recent Company Milestones

Published: 11/15/2021 12:24 GMT
LogicBio Therapeutics Inc (LOGC) - Logicbio Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Company Milestones.
Q3 Loss per Share $0.31.
Q3 Revenue $2.1 Million.
Current Cash and Cash Equivalents of $59.6 Million Will Fund Operating Expenses and Capital Expenditures Into Q4 2022.
Revenue is expected to be $1.45 Million
Adjusted EPS is expected to be -$0.31

Next Quarter Revenue Guidance is expected to be $1.45 Million
Next Quarter EPS Guidance is expected to be -$0.34

More details on our Analysts Page.